Skip to main content

TOLREMO receives 39 million US dollars in investments

| News

TOLREMO receives 39 million US dollars in investments


TOLREMO Therapeutics has concluded a series A funding round with 39 million US dollars. The biotech company based in Basel can use this to conduct its first study involving humans. TOLREMO is pursuing a differentiated approach to prevent nongenetic drug resistance in cancer.

TOLREMO Therapeutics AG has received a total of 39 million US dollars in a series A funding round. The round was led by Basel-based BioMedPartners. Pierre Fabre Invest, the investment subsidiary of France’s Pierre Fabre Group, and existing investors were also involved.

The biotech company founded in 2017 is part of the portfolio of BaseLaunch, the Basel-based biotechnology development accelerator. Its headquarters are based in Tech Park Basel. According to a press release, its mission is to stop nongenetic cancer drug resistance as it emerges. To do so, its oral drug candidate TT125-802 disarms cancer’s earliest defenses to targeted therapies, thereby surmounting a universal challenge for current and future targeted therapies.

First study in humans

The series A funding will lead to the first study in humans involving patients with solid tumors for this leading drug candidate, according to information from the company. TOLREMO’s Co-Founder and CEO Dr. Stefanie Flückiger-Mangual commented that cancer drug resistance is a significant obstacle to long-term survival. It is usually addressed in the later phases of treatment after genetic mutations have already made the cancer permanently resistant to therapy. She went on to add that TOLREMO’s drug candidate “has the potential to prevent therapy evasion and significantly improve treatment durability.”

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.